Sibia Neurosciences Begins Phase I Trial Of Antiparkinson Drug
http://www.reutershealth.com/news/docs/199702/19970219ddc.html
WESTPORT, Feb 19 (Reuters) - Sibia Neurosciences, based in La
Jolla, CA, has commenced Phase I trials of its neuronal nicotinic
acetylcholine receptor agonist, SIB-1508Y, in patients with
Parkinson's disease.
According to a Sibia press release posted on PR Newswire, the
company believes that the drug could be more effective and cause
fewer side effects than existing drugs because of its
subtype-selective activity. Dr. William T. Comer, president and
CEO of Sibia, said, "SIB-1508Y is the first selective nicotinic
agonist being evaluated in Parkinson's patients, and we believe
that this novel mechanistic approach will provide significant
benefits to patients."
_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/
_/ _/
_/ Central Supply & Services _/
_/ (Internet Training and Research) _/
_/ PO Box 57247, Jackson Stn., _/
_/ Hamilton, Ontario, Canada, L8P 4X1 _/
_/ John S. Walker _/
_/ Email [log in to unmask] _/
_/ _/
_/ "To Teach is to touch a life forever" _/
_/ On the Web one touch can reach so far! _/
_/ _/
_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/
